Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -34,105 | -22,711 | -12,361 | -5,026 | -42,194 |
| Depreciation Amortization | 4,556 | 3,789 | 2,871 | 1,901 | 3,745 |
| Accounts receivable | N/A | N/A | N/A | -193 | 5,557 |
| Accounts payable and accrued liabilities | 923 | 333 | 198 | 243 | -2,702 |
| Other Working Capital | -2,299 | -415 | -2,511 | -2,774 | 2,326 |
| Other Operating Activity | -3,367 | -5,757 | -6,665 | -4,901 | 8,148 |
| Operating Cash Flow | $-34,292 | $-24,760 | $-18,468 | $-10,750 | $-25,119 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -337 | -282 | -182 | -129 | -153 |
| Purchase Of Investment | -37,446 | -36,138 | -31,335 | -31,230 | N/A |
| Sale Of Investment | 25,821 | 15,126 | 11,376 | N/A | N/A |
| Investing Cash Flow | $-11,962 | $-21,293 | $-20,140 | $-31,359 | $-153 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 516 | N/A | N/A | N/A | 765 |
| Debt Repayment | -132 | -98 | -65 | -32 | -127 |
| Common Stock Issued | 20 | 20 | 20 | 20 | 67,164 |
| Other Financing Activity | -1,577 | -1,312 | -671 | -383 | -1,029 |
| Financing Cash Flow | $-1,173 | $-1,390 | $-716 | $-394 | $66,773 |
| Exchange Rate Effect | -241 | 48 | 0 | -28 | 18 |
| Beginning Cash Position | 56,566 | 56,566 | 56,566 | 56,566 | 15,047 |
| End Cash Position | 8,898 | 9,171 | 17,242 | 14,034 | 56,566 |
| Net Cash Flow | $-47,668 | $-47,395 | $-39,324 | $-42,532 | $41,519 |
| Free Cash Flow | |||||
| Operating Cash Flow | -34,292 | -24,760 | -18,468 | -10,750 | -25,119 |
| Capital Expenditure | -337 | -282 | -182 | -129 | -197 |
| Free Cash Flow | -34,629 | -25,042 | -18,649 | -10,879 | -25,317 |